TEE
AGTC

Tibra Equities Europe’s Applied Genetic Technologies Corporation AGTC Stock Holding History

Tibra Equities Europe’s Portfolio AGTC Stock Details AGTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-78,100
Closed -$305K – 240
2021
Q2 		$305K Buy
+78,100
New +$324K 0.09% 174

Other funds holding AGTC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Tibra Equities Europe's AGTC Position: Q3 2021 in Review

Tibra Equities Europe sold out of Applied Genetic Technologies Corporation (AGTC) in Q3 2021, closing a stake of 78,100 shares — an estimated $305K sold.

Tibra Equities Europe first reported a position in AGTC in Q2 2021 and held it in 1 quarter. The position peaked at $305K in Q2 2021. 64 funds tracked by Wall St. Rank hold AGTC as of Q3 2021.

  • Tibra Equities Europe reported no remaining Applied Genetic Technologies Corporation position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 78,100 Applied Genetic Technologies Corporation shares in Q3 2021, an estimated $305K.
  • Tibra Equities Europe first reported a position in Applied Genetic Technologies Corporation in Q2 2021 and held it in 1 quarter.
  • Tibra Equities Europe's Applied Genetic Technologies Corporation position peaked at $305K in Q2 2021.
  • 64 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.